Photo of Rona Yaeger from MSKCC/LinkedIn
Jun 27, 2024, 11:18
FDA approves the targeted therapy adagrasib for people with advanced colorectal cancer – MSKCC
Memorial Sloan Kettering Cancer Center shared a post on LinkedIn:
“The US Food and Drug Administration has approved the targeted therapy adagrasib in combination with another targeted therapy for people with advanced colorectal cancer caused by a gene mutation called KRAS-G12C. Dr. Rona Yaeger, a gastrointestinal oncologist at Memorial Sloan Kettering Cancer Center (MSK), led the trial that resulted in this approval.
“Since we started this trial, I have had people coming to me from all over to receive this treatment,” Dr. Yaeger says. “Now that this drug combination is approved, many more patients will be able to benefit.”
Learn more here.”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 14, 2024, 17:57
Nov 14, 2024, 17:46
Nov 14, 2024, 17:46
Nov 14, 2024, 17:42
Nov 14, 2024, 17:14